New trends of nanofluids to combat Staphylococcus aureus in clinical isolates

Methicillin-resistant Staphylococcus aureus (MRSA), multi-drug-resistant (MDR) Staphylococcus aureus and sensitive Staphylococcus aureus were selected for this study to check the antibacterial effects of gold nanoparticles and drug-conjugated gold nanoparticles to overcome the emerging drug resistance. Culture and purification of selected bacterial isolates, drug profiling, minimum inhibitory concentration, preparation of gold salt solution, preparation of drug-conjugated gold nanoparticles and susceptibility pattern by well diffusion assay and disk diffusion method is performed to evaluate the results. MRSA (sample MBH-2), sensitive strain (sample MBH-3) and MDR strain (sample MBH-1) showed different patterns of susceptibility. We analyzed that the drug-conjugated nanoparticles showed remarkable antibacterial activity against all three strains of S. aureus . The best bactericidal activity was observed at 100 µL gold nanoparticles concentration for all three strains. The minimal inhibitory concentration was 47, 53 and 51 mM for MRSA, MDR and sensitive S.aureus , respectively, which further approves that drug-conjugated AuNPs are more effective than the drug alone nanoparticles are smaller in size and great antimicrobial activity in our study we have seen remarkable antimicrobial activity of drug-conjugated gold nanoparticles against staphylococcus aureus shown in well diffusion assay and disk diffusion assay, we also analyzed minimum inhibitory concentration of drug-conjugated gold nanoparticles. Its recommended that future use of drug-conjugated gold nanoparticles should be used to overcome the developing drug resistance in health care facilities, because nanoparticles have very smaller size and large surface area thus it can carry large amount of drug on their targets.